Skip to content
10-Q

Quarterly Report

SUTRO BIOPHARMA, INC. STRO

0001193125-26-224170

← back to feed
Filed
May 14, 2026 12:00 AM ET
Period of report
Restated figures. One or more values in this filing restate previously reported amounts.

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding Q1 2026 · May 8, 2026 16.57M sh
Shares Diluted Q1 2026 · Mar 31, 2026 13.08M sh
Shares Diluted restated Q1 2026 · Mar 31, 2025 8.36M sh
Operating Cash Flow Q1 2026 · Mar 31, 2026 −$42.26M
Operating Cash Flow Q1 2026 · Mar 31, 2025 −$67.88M
Cash And Equivalents Q1 2026 · Mar 31, 2026 $73.68M
Cash And Equivalents Q1 2026 · Dec 31, 2025 $58.13M
Cash And Equivalents Q1 2026 · Mar 31, 2025 $106.23M
Stockholders Equity Q1 2026 · Mar 31, 2026 −$66.89M
Stockholders Equity Q1 2026 · Dec 31, 2025 −$132.45M
Stockholders Equity Q1 2026 · Mar 31, 2025 −$25.81M
Stockholders Equity Q1 2026 · Dec 31, 2024 $44.6M
Current Liabilities Q1 2026 · Mar 31, 2026 $70.81M
Current Liabilities Q1 2026 · Dec 31, 2025 $75.13M
Total Liabilities Q1 2026 · Mar 31, 2026 $308.88M
Total Liabilities Q1 2026 · Dec 31, 2025 $306.28M
Current Assets Q1 2026 · Mar 31, 2026 $220.97M
Current Assets Q1 2026 · Dec 31, 2025 $150.93M
Total Assets Q1 2026 · Mar 31, 2026 $241.99M
Total Assets Q1 2026 · Dec 31, 2025 $173.83M
Eps Diluted Q1 2026 · Mar 31, 2026 −$2.94
Eps Diluted restated Q1 2026 · Mar 31, 2025 −$9.08
Eps Basic Q1 2026 · Mar 31, 2026 −$2.94
Eps Basic restated Q1 2026 · Mar 31, 2025 −$9.08
Sga Expense Q1 2026 · Mar 31, 2026 $7.58M
Sga Expense Q1 2026 · Mar 31, 2025 $13.27M
Rd Expense Q1 2026 · Mar 31, 2026 $36.55M
Rd Expense Q1 2026 · Mar 31, 2025 $51.6M
Net Income Q1 2026 · Mar 31, 2026 −$38.48M
Net Income Q1 2026 · Mar 31, 2025 −$75.97M
Operating Income Q1 2026 · Mar 31, 2026 −$29.66M
Operating Income Q1 2026 · Mar 31, 2025 −$68.51M
Revenue Q1 2026 · Mar 31, 2026 $14.52M
Revenue Q1 2026 · Mar 31, 2025 $17.4M